持田製薬 announced the initiation of a Phase III clinical trial in Japan for BON-001 for nausea and vomiting associated with pregnancy. The announcement was made on 26 October 2026 as a timely disclosure.
持田製薬 announced that it will initiate a Phase III clinical trial in Japan for BON-001 for nausea and vomiting associated with pregnancy.
The announcement was made as a timely disclosure, and the body of the notice does not provide specific figures or dates, such as the timing of the trial.
The trial marks a new stage in the clinical development of BON-001 in the Japanese market, and further details on its progress are expected to emerge in subsequent updates.